• Home
• prostate cancer treatment
• advanced prostate cancer
• lung cancer treatment
• small cell lung cancer

prostate cancer drug

FDA accepts Watson Pharmaceutical application for longer-lasting prostate cancer drug (Canadian Business)
CORONA, Calif. (AP) - Watson Pharmaceuticals said federal health officials should make a decision on a long-lasting version of its prostate cancer drug Trelstar by third quarter 2009.

Local Business Briefs - 11/14 (The Press-Enterprise)
Watson Pharmaceuticals Inc. will seek approval for a new drug that helps treat advanced prostate cancer, according to a statement from the Corona company released Thursday.

Dendreon At The Mercy Of Provenge (Forbes)
The drug developer reports a wider loss waiting on its prostate cancer drug.

Dendreon narrows quarterly loss (Seattle Times)
Dendreon reported a net quarterly loss of $17.3 million, down from $19.8 million for the same period last year.

Dendreon 3Q loss grows on stock warrant charge (AP via Yahoo! Finance)
Drug developer Dendreon Corp. on Friday said expenses connected to its April stock offering pushed its third-quarter loss up 39 percent.

Losses no problem for GTx stock (Memphis Commercial Appeal)
Memphis-based drug company GTx Inc. reported more losses this week as it continues its expensive quest to bring new medicines onto the market. Third-quarter losses were $11.9 million, or 33 cents per share, larger than the losses of $10.2 million and 29 cents per share in the year-ago quarter.

Dendreon 3Q loss grows on stock warrant charge (INO News)
(AP:SEATTLE) Drug developer Dendreon Corp. on Friday said expenses connected to its April stock offering pushed its third-quarter loss up 39 percent. The company's loss expanded to $26.8 million, or 29 cents per share, from $19.2 million, or 23 cents per share, a year earlier.